-
Update on Lupuzor™ Pivotal Phase III Study
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study Summary 200 patients successfully recruited and randomised (dosed) 7 Countries and…
-
Notification of Major Interest by Legal & General
ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma’s total voting rights figure of 132,522,985 Ordinary Shares.…
-
Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled “Accelerated Bookbuild for the Issue of Equity”, the accelerated Bookbuild, which was oversubscribed, has now closed. The Company has raised a total of £4.1 million (before expenses) by way of an issue…
-
Accelerated Bookbuild for the Issue of Equity
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a proposed placing, raising a minimum of £3 million (before expenses), via the issue of new ordinary shares of 10p each (“Ordinary Shares”) to new and existing investors (the “New Share Placing”). The New Share Placing will provide ImmuPharma with additional…
-
Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide further details of patient …
-
Change of Adviser
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect.
-
Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that patient recruitment has successfully been completed, on target, within the Company’s pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Commenting on this announcement, Tim McCarthy, Chairman…
-
Update on Cancer Compound IPP-204106 ‘Nucant’
Mechanism of Action Published in Prestigious Medical Journal ‘Cancer Research’ ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company, is pleased to announce that Cancer Research, the prestigious medical journal of the American Association for Cancer Research (“AACR”), has published a fundamental scientific paper disclosing the mechanism…
-
Notification of Major Interest by Legal & General
ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,285,714 million Ordinary Shares in the capital of the Company, representing 3.43% of ImmuPharma’s total voting rights. Commenting, Tim McCarthy, Chairman of…
-
TR1 Notification of Major Interest
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP (“Lanstead”). Lanstead’s holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%. For full disclosure of the TR1 click here
